Apposite Capital

Type

Venture Capital

Status

Active

Location

London, United Kingdom

Total investments

20

Average round size

19M

Portfolio companies

14

Rounds per year

1.18

Lead investments

8

Follow on index

0.30

Exits

5

Stages of investment
Early Stage VentureLate Stage Venture
Areas of investment
BiotechnologySoftwareHealth CareHospitalMedical DeviceMedicalLife SciencePharmaceuticalTherapeuticsBiopharma

Summary

In 2006 was created Apposite Capital, which is appeared as VC. The fund was located in Europe if to be more exact in United Kingdom. The leading representative office of defined VC is situated in the London.

The higher amount of exits for fund were in 2015. The common things for fund are deals in the range of 10 - 50 millions dollars. The real fund results show that this VC is 27 percentage points more often commits exit comparing to other companies. The important activity for fund was in 2009. Despite it in 2019 the fund had an activity. This Apposite Capital works on 0 percentage points more the average amount of lead investments comparing to the other organizations. The fund is constantly included in less than 2 deals per year.

The fund has exact preference in a number of founders of portfolio startups. In case when startup counts 4 or 5+ of the founder, the chance for it to get the investment is meager. Among the various public portfolio startups of the fund, we may underline Anaphore, Bird Rock Bio, Ambrx Moreover, a startup needs to be at the age of 6-10 years to get the investment from the fund. For fund there is no match between the country of its foundation and the country of its the most frequent investments - United States. Among the most popular fund investment industries, there are Life Science, Health Care.

The typical case for the fund is to invest in rounds with 4-5 participants. Despite the Apposite Capital, startups are often financed by 5AM Ventures, Versant Ventures, Tavistock Life Sciences. The meaningful sponsors for the fund in investment in the same round are Versant Ventures, 5AM Ventures, Roche Venture Fund. In the next rounds fund is usually obtained by M Ventures, Versant Ventures, SR One.

Besides them, we counted 4 critical employees of this fund in our database.

Show more

Investor highlights

Industry focus
HealthcareMedtechBiotech/Life Sciences
Geo focus
AlbaniaAustriaBelgiumBosnia and HerzegovinaBulgaria Show 36 more

Discover reliable insights

Find relevant VC investors, identify key contacts and secure funding opportunities.

Investments analytics

Last fund

Fund size
GBP 200000000
Fund raised date
2022-09-28

Analytics

Total investments
20
Lead investments
8
Exits
5
Rounds per year
1.18
Follow on index
0.30
Investments by industry
  • Health Care (11)
  • Biotechnology (11)
  • Medical (9)
  • Biopharma (6)
  • Therapeutics (5)
  • Show 11 more
Investments by region
  • United States (10)
  • United Kingdom (9)
  • Spain (1)
Peak activity year
2009

Discover reliable insights

Leverage validated data, identify key contacts and secure funding opportunities for your business.

Quantitative data

Avg. startup age at the time of investment
15
Avg. valuation at time of investment
120M
Group Appearance index
0.65
Avg. company exit year
7
Avg. multiplicator
15.03
Strategy success index
0.60

Need more data?

Get access to full data about investors, including their team, contact information, and historic data.

Latest deals

Company name Deal date Industry Deal stage Deal size Location
Ulthera 08 Feb 2011 Beauty, Health Care, Medical Late Stage Venture 10M United States, Arizona, Mesa

Similar funds

By same location

By same geo focus

By doing lead investments

How we get our data

At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).

Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.